Abstract
Constitutively active HER2/neu activates nuclear factor kappa-B (NF-κB) in cells and induces their resistance to apoptotic stimuli such as tumor necrosis factor-α (TNF-α). Here, we show that integrin-linked kinase (ILK), the crucial signal transducer in the integrin pathway, is involved in HER2/neu-mediated activation of NF-κB. Expression of HER2/neu increases ILK activity. Blocking ILK activity with a kinase-deficient mutant ILK (ILK-KD) inhibits NF-κB activation and sensitizes HER2/neu-transformed cells to TNF-α-induced apoptosis. Stable expression of ILK-KD in HER2/neu-transformed cells suppressed Akt phosphorylation and the expression of IκB kinase α and β (IKKα and β) at both the protein and mRNA levels, preventing IκB-α degradation and NF-κB activation. Furthermore, HER2/neu stimulated the transcriptional activity of the putative IKKβ promoter through ILK and Akt. Our results demonstrate that upregulation of IKKα and IKKβ by the ILK/Akt pathway is required for the HER2/neu-mediated NF-κB antiapoptotic pathway.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cruet-Hennequart S, Maubant S, Luis J, Gauduchon P, Staedel C and Dedhar S . (2003). Oncogene, 22, 1688–1702.
Datta SR, Brunet A and Greenberg ME . (1999). Genes Dev., 13, 2905–2927.
Delcommenne M, Tan C, Gray V, Rue L, Woodgett J and Dedhar S . (1998). Proc. Natl. Acad. Sci. USA, 95, 11211–11216.
Downward J . (1998). Curr. Opin. Cell Biol., 10, 262–267.
Galang CK, Garcia-Ramirez J, Solski PA, Westwick JK, Der CJ, Neznanov NN, Oshima RG and Hauser CA . (1996). J. Biol. Chem., 271, 7992–7998.
Gambaletta D, Marchetti A, Benedetti L, Mercurio AM, Sacchi A and Falcioni R . (2000). J. Biol. Chem., 275, 10604–10610.
Gary DS, Milhavet O, Camandola S and Mattson MP . (2003). J. Neurochem., 84, 878–890.
Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, Bell JC and Dedhar S . (1996). Nature, 379, 91–96.
Hung MC and Lau YK . (1999). Semin. Oncol., 26, 51–59.
Karin M, Cao Y, Greten FR and Li ZW . (2002). Nat. Rev. Cancer, 2, 301–310.
Lee RJ, Albanese C, Fu M, D’Amico M, Lin B, Watanabe G, Haines III GK, Siegel PM, Hung MC, Yarden Y, Horowitz JM, Muller WJ and Pestell RG . (2000). Mol. Cell. Biol., 20, 672–683.
Lee FS, Peters RT, Dang LC and Maniatis T . (1998). Proc. Natl. Acad. Sci. USA, 95, 9319–9324.
Ling L, Cao Z and Goeddel DV . (1998). Proc. Natl. Acad. Sci. USA, 95, 3792–3797.
Malinin NL, Boldin MP, Kovalenko AV and Wallach D . (1997). Nature, 385, 540–544.
Morino N, Mimura T, Hamasaki K, Tobe K, Ueki K, Kikuchi K, Takehara K, Kadowaki T, Yazaki Y and Nojima Y . (1995). J. Biol. Chem., 270, 269–273.
Nakano H, Shindo M, Sakon S, Nishinaka S, Mihara M, Yagita H and Okumura K . (1998). Proc. Natl. Acad. Sci. USA, 95, 3537–3542.
Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM and Donner DB . (1999). Nature, 401, 82–85.
Palombella VJ, Rando OJ, Goldberg AL and Maniatis T . (1994). Cell, 78, 773–785.
Radeva G, Petrocelli T, Behrend E, Leung-Hagesteijn C, Filmus J, Slingerland J and Dedhar S . (1997). J. Biol. Chem., 272, 13937–13944.
Renshaw MW, Ren XD and Schwartz MA . (1997). EMBO J., 16, 5592–5599.
Romashkova JA and Makarov SS . (1999). Nature, 401, 86–90.
Sundberg C and Rubin K . (1996). J. Cell Biol., 132, 741–752.
Tan M, Jing T, Lan KH, Neal CL, Li P, Lee S, Fang D, Nagata Y, Liu J, Arlinghaus R, Hung MC and Yu D . (2002b). Mol. Cell, 9, 993–1004.
Tan C, Mui A and Dedhar S . (2002a). J. Biol. Chem., 277, 3109–3116.
Thanos D and Maniatis T . (1995). Cell, 80, 529–532.
Yu D and Hung MC . (2000). Oncogene, 19, 6115–6121.
Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, Lin SY and Hung MC . (2000). J. Biol. Chem., 275, 8027–8031.
Zhou BP, Liao Y, Xia W, Zou Y, Spohn B and Hung MC . (2001). Nat. Cell Biol., 3, 973–982.
Zhu X and Assoian RK . (1995). Mol. Cell. Biol., 6, 273–282.
Acknowledgements
We thank Dr Shoukat Dedhar (University of British Columbia, British Columbia, Canada) for providing the ILK and ILK-KD plasmids. This work is supported by NIH PO1 CA 99031 and RO1 58880 (to M.-C.H.).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Makino, K., Day, CP., Wang, SC. et al. Upregulation of IKKα/IKKβ by integrin-linked kinase is required for HER2/neu-induced NF-κB antiapoptotic pathway. Oncogene 23, 3883–3887 (2004). https://doi.org/10.1038/sj.onc.1207485
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207485
Keywords
This article is cited by
-
An increase in integrin-linked kinase non-canonically confers NF-κB-mediated growth advantages to gastric cancer cells by activating ERK1/2
Cell Communication and Signaling (2014)
-
Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer
Breast Cancer (2012)
-
Inhibition of high glucose-induced VEGF and ICAM-1 expression in human retinal pigment epithelium cells by targeting ILK with small interference RNA
Molecular Biology Reports (2012)
-
Her2 activates NF-κB and induces invasion through the canonical pathway involving IKKα
Oncogene (2010)
-
ABINs inhibit EGF receptor-mediated NF-κB activation and growth of EGF receptor-overexpressing tumour cells
Oncogene (2008)